Apellis Pharmaceuticals Inc (APLS)

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600May 7, 2026 6:01 PM
PR Newswire (US) NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE: BFAM) will replace Tri Pointe Homes Inc. (NYSE: TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.Remitly Global Inc. (NASD: RELY) will replace Apellis Pharmaceuticals Inc. (NASD: APLS). S&P 500 constituent Biogen Inc. (NASD: BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorMay 14, 2026S&P SmallCap 600AdditionBright Horizons Family SolutionsBFAMConsumer DiscretionaryMay 14, 2026S&P SmallCap 600DeletionTri Pointe HomesTPHConsumer DiscretionaryMay 14, 2026S&P SmallCap 600AdditionRemitly GlobalRELYFinancialsMay 14, 2026S&P SmallCap 600DeletionApellis PharmaceuticalsAPLSHealth CareABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.FOR MORE INFORMATION:S&P Dow Jones Indices
index_services@spglobal.comMedia Inquiries
spdji.comms@spglobal.com View original content:https://www.prnewswire.com/news-releases/bright-horizons-family-solutions-and-remitly-global-set-to-join-sp-smallcap-600-302766326.htmlSOURCE S&P Dow Jones Indices Original: Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Found Early: $APLS - Up 135% - #DDAmanda Chart

Find the next one: https://DDAmanda.com



Z

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600January 27, 2026 11:02 PM
PR Newswire (US)

NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:
S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE: CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE: SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE: BROS) will replace PotlatchDeltic Corp. (NASD: PCH) in the S&P MidCap 400 effective prior to the opening of trading on Monday, February 2. S&P MidCap 400 constituent Rayonier Inc. (NYSE: RYN) is acquiring PotlatchDeltic in a deal expected to be completed soon, pending final closing conditions. Rayonier will remain in the S&P MidCap 400 post-merger.S&P SmallCap 600 constituent Advanced Energy Industries Inc. (NASD: AEIS) will replace Comerica Inc. (NYSE: CMA) in the S&P MidCap 400, and Apellis Pharmaceuticals Inc. (NASD: APLS) will replace Advanced Energy Industries in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 2. S&P 500 constituent Fifth Third Bancorp (NASD: FITB) is acquiring Comerica in a deal expected to be completed soon, pending final closing conditions.American Healthcare REIT Inc. (NYSE: AHR) will replace Cadence Bank (NYSE: CADE) in the S&P MidCap 400 effective prior to the opening of trading on Monday, February 2. S&P 500 constituent Huntington Bancshares Inc. (NASD: HBAN) is acquiring Cadence Bank in a deal expected to be completed soon, pending final closing conditions.LegalZoom.com Inc. (NASD: LZ) will replace Elme Communities (NYSE: ELME) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 2. Elme Communities has announced ongoing liquidation activities and is no longer appropriate for the S&P SmallCap 600.Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJan 30, 2026S&P MidCap 400AdditionTTM TechnologiesTTMIInformation TechnologyJan 30, 2026S&P MidCap 400DeletionCivitas ResourcesCIVIEnergyJan 30, 2026S&P SmallCap 600AdditionAmneal PharmaceuticalsAMRXHealth CareJan 30, 2026S&P SmallCap 600DeletionTTM TechnologiesTTMIInformation TechnologyFeb 2, 2026S&P MidCap 400AdditionDutch BrosBROSConsumer DiscretionaryFeb 2, 2026S&P MidCap 400AdditionAdvanced Energy IndustriesAEISInformation TechnologyFeb 2, 2026S&P MidCap 400AdditionAmerican Healthcare REITAHRReal EstateFeb 2, 2026S&P MidCap 400DeletionComericaCMAFinancialsFeb 2, 2026S&P MidCap 400DeletionCadence BankCADEFinancialsFeb 2, 2026S&P MidCap 400DeletionPotlatchDelticPCHReal EstateFeb 2, 2026S&P SmallCap 600AdditionApellis PharmaceuticalsAPLSHealth CareFeb 2, 2026S&P SmallCap 600AdditionLegalZoom.comLZIndustrialsFeb 2, 2026S&P SmallCap 600DeletionAdvanced Energy IndustriesAEISInformation TechnologyFeb 2, 2026S&P SmallCap 600DeletionElme CommunitiesELMEReal EstateABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.FOR MORE INFORMATION:S&P Dow Jones Indices
index_services@spglobal.com Media Inquiries
spdji.comms@spglobal.com



View original content:https://www.prnewswire.com/news-releases/ttm-technologies-dutch-bros-advanced-energy-industries-and-american-healthcare-reit-set-to-join-sp-midcap-400-others-to-join-sp-smallcap-600-302671845.htmlSOURCE S&P Dow Jones Indices

Original: TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

IKT is having a great run!

APLS at a bottom channel

$60.00, that didn’t take long!

I like the way this traded today, $60 in the near future on news?

Holding up well..

Finally! Back up 14% today.

Shorts got another 12 to 13% since you're warning, let's hope your warning sticks today...

APLS Time to Cover Shorts just like i told the shorts last week on ARGX to Buy to Cover

Closed out of puts at 99% profit on this one. Only three week hold.

Why is stock up so much???

Stock up big today.

FDA announcement soon.

Puts are very pricey and out of the money. Sell for cash to acct.

Why up today? As stock goes up, puts go up too. Strange.

Will we get FDA approval???

Heavy premium in the puts and calls.

2/8/23 regulatory decision due on Empavali.

Huge Market

Drug trial for dry AMD slows progression of disease

Posted: Tuesday 29 March 2022

A drug being trialled for dry age-related macular degeneration (AMD) can significantly reduce the progression of the disease, according to new studies.

Phase three trials have shown that injections of a drug called pegcetacoplan resulted in a significant reduction in the rate at which the cells of the macular degenerate.

The studies by Apellis Pharmaceuticals built on previous research which showed that dry AMD is linked to the complement system and a hyperactive immune response that damages the eyes. Pegcetacoplan is a complement system inhibitor, meaning it aims to prevent this response from happening and harming healthy cells and tissue.

The studies involved two phase three clinical trials (DERBY and OAKS) involving more than 1,250 patients with late stage dry AMD, often referred to as geographic atrophy (GA). As part of the trials some patients received injections monthly, while others received them every other month.

In the combined results of the two trials, patients who received the drug monthly showed up to a 21% reduction in progression of the disease after 18 months, while those who were injected every other month had a 17% reduction.

Jeffrey S. Heier, principal investigator of the DERBY study from Ophthalmic Consultants of Boston, said: “It is exciting to see these positive data with pegcetacoplan, which showed continuous and potentially improving effects over time. These 18-month results provide further evidence that pegcetacoplan meaningfully slows disease progression and has the potential to preserve vision longer.”

He added: “In my practice, I have seen how devastating it can be for people living with GA to lose more of their vision year after year. There is an urgent unmet need in GA, and these results reinforce the potential of pegcetacoplan to become the first-ever treatment for patients with this debilitating disease.”

The study also found that pegcetacoplan was generally safe and well tolerated by those on the trial.

Results of the studies are to be submitted to the US Food and Drug Administration (FDA) for review by the end of June 2022, with the hope that the drug will be licenced for use in the USA.

Going back to 60 this week

looks like insider dumping may be happening again.. damnit

Be careful with this company.
There was a great PR.
An insider dump.
Then a 7 million share under-market private placement.
Then another insider dump the next day.

Scam company.

* * $APLS Video Chart 01-07-2020 * *

Link to Video - click here to watch the technical chart video

First! Holding $40 2/21 call... waiting on trial results!